SAM CHUN DANG PHARM CO. LTD

000250 KRX Pharmaceuticals Pharmaceuticals
KOSDAQ
₩160,700.00
-3.89%
Delayed · cached 15 min

Fair value analysis

000250
SAM CHUN DANG PHARM CO. LTD
PharmaceuticalsPharmaceuticals
₩160,700.00
Close used for this calculation
₩3,327.27Fair value

The valuation models disagreed widely for this stock, so this figure is an unweighted average of the middle of their range. Treat it as indicative only.

Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
22/100
Profitability10/25
Returns0/25
Balance Sheet10/25
Efficiency2/25
Growth3/25
Weak
Quality radar
22Prof.10/25Ret.0/25Eff.2/25B.Sht10/25Growth3/25

Consensus fair value

₩3,327.27
Above FV
▼ -97.9% against the close used
Model range ₩1,765.06 – ₩7,768.62
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₩1,765.06Fair value₩3,327.27Bull₩7,768.62
FairClose
52-week traded range
52W low ₩126,500.0052W high ₩239,000.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

SAM CHUN DANG PHARM CO. LTD closed at ₩160,700.00, 4,729.8% above the consensus fair value of ₩3,327.27 drawn from 9 valuation models.

Financial DNA score 22/100 — Weak. P/E of 711.1x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₩4,235.81
-97.4%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩7,768.62
-95.2%
√(22.5 × EPS × BVPS)
EPS=226, BVPS=11868.54 · outside Graham range (P/E 711.1, P/B 13.5) — asset-light, treat as a rough floor
Graham Formula
₩2,561.33
-98.4%
EPS × (8.5 + 2g) × 4.4 ÷ FD_Rate
g=0%, FD=3.3%
P/E Fair Value
₩4,520.00
-97.2%
EPS × 20x (sector P/E)
EPS=226, Sector P/E=20x
Peter Lynch (PEG)
₩1,765.06
-98.9%
EPS × Growth% (PEG = 1 is fair)
EPS=226, g=7.8%
EV/EBITDA
₩3,075.95
-98.1%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=17.55B
Book Value (P/B)
₩2,266.89
-98.6%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=11868.54, ROE=1.9%, g=3%, r=10%
Reverse DCF
₩160,700.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 50% | Historical: -7.8%
Margin of Safety
₩3,578.58
-97.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=4771.44, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.